Clinical Trial Update: Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating NVA237 (umeclidinium) on exercise endurance in chronic obstructive pulmonary disease; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• NVA237 (umeclidinium) (umeclidinium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2012-05-07